BeOne Medicines Ltd. (ONC)
390.94
-8.76
(-2.19%)
USD |
NASDAQ |
Nov 20, 16:00
390.94
0.00 (0.00%)
After-Hours: 20:00
BeOne Medicines Research and Development Expense (TTM) : 2.359B for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 2.359B |
| June 30, 2026 | 2.220B |
| March 31, 2026 | 2.137B |
| December 31, 2025 | 2.079B |
| September 30, 2025 | 1.997B |
| June 30, 2025 | 1.944B |
| March 31, 2025 | 1.865B |
| December 31, 2024 | 1.838B |
| September 30, 2024 | 1.794B |
| June 30, 2024 | 1.774B |
| March 31, 2024 | 1.745B |
| December 31, 2023 | 1.698B |
| September 30, 2023 | 1.654B |
| June 30, 2023 | 1.646B |
| March 31, 2023 | 1.606B |
| December 31, 2022 | 1.592B |
| September 30, 2022 | 1.582B |
| June 30, 2022 | 1.508B |
| March 31, 2022 | 1.491B |
| December 31, 2021 | 1.428B |
| September 30, 2021 | 1.356B |
| Date | Value |
|---|---|
| June 30, 2021 | 1.345B |
| March 31, 2021 | 1.278B |
| December 31, 2020 | 1.264B |
| September 30, 2020 | 1.192B |
| June 30, 2020 | 1.085B |
| March 31, 2020 | 1.032B |
| December 31, 2019 | 910.05M |
| September 30, 2019 | 888.69M |
| June 30, 2019 | 800.80M |
| March 31, 2019 | 737.56M |
| December 31, 2018 | 670.00M |
| September 30, 2018 | 504.89M |
| June 30, 2018 | 445.93M |
| March 31, 2018 | 330.48M |
| December 31, 2017 | 264.68M |
| September 30, 2017 | 203.50M |
| June 30, 2017 | 146.68M |
| March 31, 2017 | 120.60M |
| December 31, 2016 | 96.12M |
| September 30, 2016 | 95.77M |
| June 30, 2016 | 96.31M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Basilea Pharmaceutica AG | 153.18M |
| Santhera Pharmaceuticals Holding AG | 25.76M |
| AC Immune SA | 53.66M |
| CRISPR Therapeutics AG | 278.98M |
| Idorsia Ltd. | 126.33M |